Background: The identification of new biomarkers is required for early diagnosis of colorectal carcinoma patients (CRC), since about 20% of these patients are initially diagnosed with a distant metastatic disease. GRP78, a heat shock protein, functions also as a cell surface signaling receptor of cells under physiological stress. GRP78 was found to be expressed on the cell surface of various tumor cells. The presence of autoantibodies to GRP78 in cancer patient's serum was found to be correlated with a poor prognosis. In this study we aimed to identify anti-GRP78 antibodies in the serum of 85 patients diagnosed by colonoscopy, as an early detection biomarker.
Methods: We developed an ELISA assay with recombinant GRP78 immobilized on 96-well culture plates and used an anti-IgG antibody to measure the sole anti-GRP78 IgGs.
Results: Testing for anti-GRP78 showed a significant increase in antibody titer in patients with a polyp and in CRC patients (p<0.001) compared to healthy subjects.
Conclusions: This is the first study showing the presence of anti-GRP78 at the very early stages of CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/jbm.5000086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small molecules targeting GRP78 mitigate anti-GRP78 autoantibody-mediated tissue factor procoagulant activity in cultured endothelial cells.
J Thromb Haemost
November 2024
Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and The Hamilton Center for Kidney Research, Hamilton, Ontario, Canada. Electronic address:
Background: The 78-kDa glucose-regulated protein (GRP78) expressed on the cell surface (csGRP78) has been reported to regulate tissue factor (TF) procoagulant activity (PCA) in lesion-resident endothelial cells (ECs), which is further enhanced by circulating anti-GRP78 autoantibodies that bind to the Leu-Leu epitope in GRP78.
Objectives: Determine the effects of the engagement of the anti-GRP78 autoantibody to csGRP78 on ECs and the underlying mechanisms that impact TF PCA.
Methods: Immunofluorescent staining was used to determine the presence of csGRP78 in tumor necrosis factor α-treated ECs.
Synthetic Antibody Mimics Based on Cancer-Targeting Immunostimulatory Peptides.
Chembiochem
May 2021
Department of Biological Sciences and Chemistry and Biochemistry, Seton Hall University, 400 South Orange Avenue, South Orange, NJ 07079, USA.
De novo cancer-targeting immunostimulatory peptides have been designed and developed as synthetic antibody mimics. A series of bifunctional peptides incorporating NKp30-binding and NK-cell-activating domains were synthesized as linear dimers and then extended into branching trimeric peptides by the incorporation of GRP78-targeting and tumor-cell-binding sequences. A selected trimeric peptide from this small set of peptides displayed binding capabilities on GRP78 HepG2 and A549 target cells.
View Article and Find Full Text PDFAnti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions.
JCI Insight
December 2018
Department of Biochemistry and Biomedical Sciences.
Article Synopsis
- GRP78 is a protein involved in proper protein folding in the endoplasmic reticulum but can become a cancer-promoting receptor on cell surfaces under stress.
- Anti-GRP78 autoantibodies are produced in conditions like atherosclerosis, particularly in ApoE-/- mice, and are linked to increased growth of vascular lesions.
- Disrupting the interaction between these autoantibodies and GRP78 may offer a new therapeutic approach to slow down atherosclerosis progression.
ROS-independent Nrf2 activation in prostate cancer.
Oncotarget
September 2017
Department of Experimental Medicine, University of Perugia, Perugia, Italy.
In prostate cancer, oxidative stress and the subsequent Nrf2 activation promote the survival of cancer cells and acquired chemoresistance. Nrf2 links prostate cancer to endoplasmic reticulum stress, an event that triggers the unfolded protein response, aiming to restore cellular homeostasis as well as an adaptive survival mechanism. Glucose-regulated protein of 78 kD /immunoglobulin heavy chain binding protein (GRP78/BiP) is a key molecular chaperone in the endoplasmic reticulum that, when expressed at the cell surface, acts as a receptor for several signaling pathways enhancing antiapoptotic and proliferative signals.
View Article and Find Full Text PDFImmunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.
Oncoimmunology
July 2016
Peter MacCallum Cancer Center and The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne ,Victoria, Australia; The Department of Pathology, University of Melbourne, Melbourne Victoria, Australia.
The presence of tumor immune infiltrating cells (TILs), particularly CD8(+) T-cells, is a robust predictor of outcome in patients with colorectal cancer (CRC). We revisited TIL abundance specifically in patients with microsatellite stable (MSS) CRC without evidence of lymph node or metastatic spread. Examination of the density of CD8(+) T-cells in primary tumors in the context of other pro-oncogenic markers was performed to investigate potential regulators of TILs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!